Loading...
First Round of Abstract Submission Ends: Apr 15, 2026
Extended Early Bird Ends: Aug 28, 2025

Programme Overview

Titles Accepted for Presentations

🌟 PLENARY TALKS

Guido Kroemer, Universite Paris Cite, France

Neuroendocrine control of the immune response

 
Stephan Grabbe, Johannes Gutenberg University Mainz, Germany

Relevance of beta-2 integrins for regulatory T cell function

 
Wolf H Fridman, University of Paris, France

Neuro-cancer mimicry: GABA modulates tumor immunity and impairs response to immunotherapy

 
Florian Sennlaub, INSERM, France

How Genetic and Environmental Risk Factors Drive Inflammation in Age-Related Macular Degeneration

 
Junji Yodoi, Kyoto University, Japan

50 Yrs Update of TRX/ADF/IgEBF and Redoxisome; Basic Regulator of Allergy, Inflammation and Stress Diseases

 
Catherine Sautès-Fridman, Cordeliers Research Centre, Paris, France

Tumor heterogeneity and immunotherapy response

 

🎤 KEYNOTE TALKS

Patrick Baeuerle,Cullinan Therapeutics, Inc., USA

The Rise of T Cell Engaging Antibodies

 
David C. Wraith,University of Birmingham, UK

Antigen-specific immunotherapy of autoimmune diseases

 
Lazaros I Sakkas,University of Thessaly, Greece

Sex bias in Systemic Sclerosis

 
Helmut Salih, University Hospital Tuebingen, Germany

From challenges to Remedies-Bispecific Antibodies in Solid Tumors” or short “Bispecific Antibodies in Solid Tumors

 
Maria LEITE DE MORAES, Université Paris Cité, France

MAIT cells in lung and skin inflammation

 
Benoit Salomon, INSERM, France

Stability and function of Foxp3 Tregs at steady state and in cancer

 
Dirk Jäger, National Center for Tumor Diseases (NCT) Heidelberg, Germany

Highly individualized immunotherapy

 
Bertrand Huard, Univ. Grenoble-Alpes, CNRS, France

A proliferation inducing ligand, an inflammatory molecule with an unexpected neuroregenerative action in multiple sclerosis lesions

 
Eyad Elkord, Xi'an Jiaotong-Liverpool University, China

T regulatory cells and immune checkpoints in cancer: Findings, challenges, and opportunities

 
Julien C. Marie, INSERM, France

Novel effector T cell subsets initiating cancer

 
Annalisa Chiocchetti, University of Eastern Piedmont, Italy

From patient to prediction: personalized clinical trials on chip to predict immunomodulatory drug response in Rheumatoid Arthritis

 
Niels Halama,The German Cancer Research Center (DKFZ), Germany

Lipid-laden macrophages as an immuno-metabolic nexus in ovarian cancer: clinical translation of innate immunity

 
Anne Astier,Infinity Institute in Toulouse, France

How risk factors for multiple sclerosis contribute to immune dysregulation

 

🎯 INVITED TALKS

Daniela Kramer, Johannes Gutenberg University in Mainz, Germany

Critical regulation of immune responses by the transcriptional cofactor IκBζ

 
Julien Faget, Univ Montpellier, ICM, INSERM, France

Deciphering cancer cell autonomous and non-autonomous STING dependent tumor-promoting functions in KrasG12/Tp53ko mouse model of lung adenocarcinoma

 
Pascale Jeannin, University of Angers, France

Ketone bodies control cellular fate and stress resistance; mechanisms involved

 
Francesco Maione, University of Naples Federico II, Naples, Italy

From Sequence To Solution: Fm15tm, A First In-Class Linear Small Peptide Antagonist Of Il-17 With Translational Potential

 
Anna Schettino, University of Naples Federico II, Naples, Italy

A Natural Strategy to Curb Inflammation: Mangifera Indica L. Extract Modulates Tlr2/4/6 Signaling to Suppress the Myd88/Nf-Κb Axis

 
Aymeric SILVIN, Institut Gustave Roussy, France

Iterative Integration of Spatial Multi-Omics and Single-Cell RNA-Seq Reveals a CSF1-Dependent Immune Hub in Anaplastic Thyroid Cancer

 
Yizhuo Zhang, Sun Yat-sen University Cancer Center, China

CAR - T Therapy for Pediatric Solid Tumors

 
Ishna Poojary-Hohman, University of South Florida, USA

Antibody mediated and acute cellular lung transplant associated rejection from the perspective of a transplant pulmonologist

 
Fu Hui, Weifang People's Hospital, China

Mechanisms of TKI Resistance in Non-Small Cell Lung Cancer and Preclinical Studies

 
Doan C. Nguyen, Emory University School of Medicine, USA

SARS-CoV-2-specific plasma cells are excluded from the bone marrow long-lived compartment after mRNA vaccination

 
Zhongming Dai, Qiu District People’s Hospital, China

Microbiota composition-based donor selection affects FMT efficacy in a murine colitis model

 
Syrine Abdeljaoued, Therapetic innovation in cancer immunology, UMR RIGHT 1098, France

Pre-encoded differentiation capacity of T cells into tissue-resident memory cells defines the outcome of immune checkpoint inhibitors

 
Moriya Tsuji, Columbia University Irving Medical Center, USA

Uncovering group 1 CD1-restricted human T cells elicited by malaria vaccination in vivo

 
Ingrid Faye,Stockholm University, Sweden

Sjögren disease like immune responses against isopentenyl pyrophosphate (IPP) in Balb/C mice

 
Vancho Bonev, Bul Bio NCIPD EAD, Bulgaria

C1q Is Recognized as a Soluble Autoantigen by Anti-C1q Antibodies of Patients with Systemic Lupus Erythematosus

 
Artem Kalinichenko, Medical University of Graz, Austria

Beyond Peptides: How T Cells Sense Metabolic Fitness

 
Qiang Sun, Laboratory of Cell Engineering, Institute of Biotechnology, P.R.China

A PSAT1 buff of YBX1 transcriptionally sustains HLA-E-mediated evasion of NK immunity